GeneChem is a manager of focused venture capital funds. Since 1997, we have been involved in the launching of companies and in the management of their growth and liquidity events.

GeneChem has been part of investment syndicates which included a wide breadth of marquee international investors as well as smaller local players. The team has knowledge and expertise in various fields of science including biochemistry, chemistry, immunology, oncology, virology, bacteriology, analgesia, ophthalmology and human genetics.

We have invested at the very early stages of start-ups, where hands-on management is required, and also at the later stages such as mezzanine rounds and private placements in public entities. The team's experience is broad and deep-reaching within the biotech investment sector.

1 Westmount Square, Suite 800
Montreal, Quebec
H3Z 2P9

T 514-849-7696
F 514-849-5191

Kevin McBride, PhD Vice President, Research

Kevin McBride joined the AmorChem team as Director, Project Management in January 2013. Dr. McBride is a multidisciplinary scientist who has more than twenty years of biomedical research and project management experience, comprising both fundamental academic research as well as applied drug discovery efforts in the biotech sector. He obtained his M.Sc. (Analytical Chemistry) degree from Queen's University (Belfast) and subsequently moved to England where he performed his doctoral research (biochemistry) at the School of Pharmacy, University of London. He became a Senior Investigator at the IRCM (Cardiac Growth & Differentiation lab) in Montreal following his postdoctoral work, and in 2001 was invited to join and lead a molecular biology team for Compatigene Inc., a biotech company working on cancer immunotherapeutics. He made significant contributions to the rapid identification of a mouse/human gene encoding an immunodominant epitope on the surface of cancer cells. After Compatigene, Kevin continued further in the biotech field by joining Chronogen Inc. (2003) where he led a team that discovered and developed an inhibitor of an anti-aging target in animals that eventually achieved proof-of-concept as a candidate Alzheimer's disease therapeutic. He remained a consultant to EnVivo Pharma Inc. after its acquisition of the Chronogen target.

T 514-849-5451
F 514-849-5191



About UsProcessPortfolioOur TeamNewsNuChemGeneChemContactFrançais

© 2018 AmorChem. All rights reserved. Developed by Grafika Designs a Montreal Web Design company.